Nolvadex (Tamoxifen Citrate)

• Nolvadex (tamoxifen citrate) acts on estrogen‑dependent pathways in breast tissue and related conditions.
• Estrogen receptor‑positive breast cancer (adjuvant therapy): reduces the risk of disease recurrence following surgery or radiation.
• Metastatic breast cancer: slows tumor progression, improves disease control and may extend overall survival.
• Prevention of breast cancer in high‑risk women: lowers the incidence of new estrogen‑driven tumors in susceptible populations.
• Gynecomastia in men: diminishes abnormal breast tissue growth and associated pain or tenderness.

• Tamoxifen citrate binds competitively to estrogen receptors in breast tissue, acting as an antagonist that blocks estrogen from attaching to the receptor. This prevents estrogen‑driven transcription of genes that promote cell proliferation and survival, thereby inhibiting the growth of estrogen‑dependent tumor cells while exerting partial agonist effects in other tissues such as bone and the uterus.

Nolvadex may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hot flashes: sudden feeling of heat and sweating.
• Nausea: mild to moderate upset stomach.
• Menstrual irregularities: changes in cycle length or flow.
• Fatigue: persistent tiredness.
• Headache: mild to moderate pain.
• Mild rash: skin irritation or redness.

Serious or Rare Side Effects

• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Endometrial cancer: abnormal uterine bleeding or growth.
• Severe liver injury: jaundice, elevated enzymes.
• Visual disturbances: blurred vision or retinal changes.
• Severe allergic reactions: anaphylaxis, swelling, difficulty breathing.
• Stroke: sudden neurological deficits.

• When prescribing Nolvadex, clinicians should observe several safety considerations to minimize risk.
• Monitor liver function: perform baseline and periodic hepatic enzyme tests.
• Assess thromboembolic risk: evaluate history of clotting disorders before initiation.
• Evaluate uterine health: consider baseline pelvic exam for women at risk of endometrial pathology.
• Counsel on pregnancy risk: avoid use during pregnancy and advise effective contraception.
• Avoid concomitant estrogen therapy: may reduce drug efficacy.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Nolvadex interacts with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower tamoxifen plasma levels.
• Warfarin: may enhance anticoagulant effect and increase INR.
• Estrogen‑containing contraceptives or hormone replacement therapy: can diminish tamoxifen’s anti‑estrogen activity.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (e.g., paroxetine, fluoxetine): may modestly affect tamoxifen metabolism.
• Anticoagulants (e.g., heparin, low‑molecular‑weight heparin): monitor for bleeding.
• CYP2D6 inhibitors (e.g., quinidine): may reduce conversion to active metabolites, adjust monitoring.